NCT07807163
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07807163
Title A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC (FORTIFI-FLEX)
Acronym FORTIFI-FLEX
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bicara Therapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Site US077 RECRUITING Fort Myers Florida 33980 United States Details
Site US078 RECRUITING Orlando Florida 32827 United States Details
Site US075 RECRUITING St. Petersburg Florida 33701 United States Details
Site US076 RECRUITING West Palm Beach Florida 33410 United States Details
Site US069 RECRUITING Baton Rouge Louisiana 70809 United States Details
Site US074 RECRUITING Tyler Texas 75702 United States Details
Site US073 RECRUITING Roanoke Virginia 24014 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field